<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vincenzo Berghella, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Identifying patients with preterm contractions who will go on to give birth preterm is an inexact process, even though preterm labor is one of the most common reasons for hospitalization in pregnancy. Accurate identification of patients in true preterm labor allows appropriate application of interventions that can improve neonatal outcome: antenatal corticosteroid therapy, antibiotic prophylaxis against early-onset neonatal group B streptococcal infection, <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> for neuroprotection, and maternal transfer to a facility with an appropriate level of newborn care (if necessary). Just as important, accurate identification of patients who are contracting but not in preterm labor avoids unnecessary and sometimes costly interventions in the approximately 50 percent of patients with suspected preterm labor who subsequently give birth at term without tocolytic therapy [<a href="#rid1">1</a>].</p><p>This topic will describe the clinical findings and diagnostic evaluation of patients who present with signs and symptoms of preterm labor, and initial treatment of those in whom a diagnosis of preterm labor is made. Incidence, risk factors, and prevention of preterm birth and tocolytic therapy for preterm labor are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality", section on 'Incidence of prematurity'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor"</a>.)</p><p></p><p class="headingAnchor" id="H1331941606"><span class="h1">PATHOGENESIS OF PRETERM LABOR</span><span class="headingEndMark"> — </span>The pathophysiology of preterm labor involves at least four primary pathogenic processes that result in a final common pathway ending in spontaneous preterm labor and birth:</p><p class="bulletIndent1"><span class="glyph">●</span>Stress-induced premature activation of the maternal or fetal hypothalamic-pituitary-adrenal axis</p><p class="bulletIndent1"><span class="glyph">●</span>Exaggerated inflammatory response/infection and/or altered genital tract microbiome</p><p class="bulletIndent1"><span class="glyph">●</span>Decidual hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Pathological uterine distention</p><p></p><p>These processes and the pathophysiology of normal labor are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6785.html" rel="external">"Spontaneous preterm birth: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/6758.html" rel="external">"Physiology of parturition at term"</a>.)</p><p class="headingAnchor" id="H1331941624"><span class="h1">CLINICAL FINDINGS</span><span class="headingEndMark"> — </span>The clinical findings that define true labor (ie, regular contractions resulting in cervical change) are the same whether labor occurs preterm or at term. The following prodromal signs and symptoms may be present for several hours before diagnostic criteria for labor are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Menstrual-like cramping</p><p class="bulletIndent1"><span class="glyph">●</span>Mild, irregular contractions</p><p class="bulletIndent1"><span class="glyph">●</span>Low back ache</p><p class="bulletIndent1"><span class="glyph">●</span>Pressure sensation in the vagina or pelvis</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal discharge of mucus, which may be clear, pink, or slightly bloody (ie, mucus plug, bloody show)</p><p class="bulletIndent1"><span class="glyph">●</span>Spotting, light bleeding</p><p></p><p>Uterine contractions are the sine qua non of labor, but mild irregular contractions are a normal finding at all stages of pregnancy, thereby adding to the challenge of distinguishing true labor (contractions that result in cervical change) from false labor (contractions that do not result in cervical change [ie, Braxton Hicks contractions]). True labor is more likely when an increasing contraction frequency is accompanied by increasing intensity and duration since an increase in the frequency alone may occur transiently, especially at night and with advancing gestational age. Although many investigators have tried, no one has been able to identify a threshold contraction frequency that effectively identifies patients who will progress to true labor. Only 13 percent of patients presenting at &lt;34 weeks of gestation who meet explicit contraction criteria for preterm labor give birth within one week [<a href="#rid2">2</a>].</p><p>Cervical changes on physical examination that precede or accompany true labor include dilation, effacement, softening, and movement to a more anterior position. The rate of cervical change distinguishes cervical ripening, which occurs over days to weeks, from true labor, in which cervical change occurs over minutes to hours. A short or a dilated cervix may be the first clinical manifestation of impending preterm labor triggered by subclinical inflammation [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H1331941715"><span class="h1">COMPONENTS OF THE DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>In most patients, the diagnostic evaluation is performed on the labor unit or a labor triage unit. However, the clinician may elect to evaluate patients with very mild, nonspecific symptoms in the office.</p><p class="headingAnchor" id="H1331941791"><span class="h2">History and initial examinations</span><span class="headingEndMark"> — </span>For the initial evaluation of patients with suspected preterm labor, the clinician should:</p><p class="bulletIndent1"><span class="glyph">●</span>Review the patient's past and present obstetric and medical history, including risk factors for preterm birth  (<a class="graphic graphic_table graphicRef68992" href="/d/graphic/68992.html" rel="external">table 1</a>). A standardized interview to screen for substance misuse is part of this review; some examples are shown in the table  (<a class="graphic graphic_table graphicRef128222" href="/d/graphic/128222.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care", section on 'Screening for substance use'</a>.)</p><p></p><p class="bulletIndent1">Although many cases appear to be idiopathic, clinicians should consider possible causes of the preterm contractions based on the history and physical examination. Preterm labor may be triggered by an underlying obstetric complication (eg, abruption) or medical/surgical disorder (eg, appendicitis, bowel obstruction or strangulation, pyelonephritis, acute cholecystitis, pneumonia, hyperthyroidism/thyroid storm) that requires specific intervention. These cases may present with additional symptoms and/or symptoms atypical for preterm labor. Sometimes, accurate diagnosis requires a high index of suspicion since laboring patients typically have abdominal pain and may have back pain, nausea, vomiting, or diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estimate gestational age, based on the best estimate from the first ultrasound examination [<a href="#rid4">4</a>]. If prior ultrasound estimation of gestational age is not available, an ultrasound examination for fetal biometry should be performed. (See  <a class="medical medical_review" href="/d/html/5391.html" rel="external">"Prenatal assessment of gestational age, date of delivery, and fetal weight"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for signs and symptoms of preterm labor. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess contraction frequency, duration, and intensity. (See  <a class="medical medical_review" href="/d/html/4445.html" rel="external">"Labor and delivery: Management of the normal first stage", section on 'Uterine contraction monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Examine the uterus to assess firmness, tenderness, fetal size, and fetal position.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review the fetal heart rate tracing. (See  <a class="medical medical_review" href="/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview"</a>.)</p><p></p><p class="headingAnchor" id="H1331945784"><span class="h2">Speculum examination</span><span class="headingEndMark"> — </span>A speculum examination is performed using a wet non-lubricated speculum (lubricants may interfere with tests performed on vaginal specimens). The goals of this examination are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Estimate cervical dilation. Cervical dilation ≥3 cm supports the diagnosis of preterm labor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess the presence and amount of uterine bleeding. Bleeding from placental abruption or placenta previa can trigger preterm labor. (See  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/d/html/6772.html" rel="external">"Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess fetal membrane status (intact or ruptured) by standard methods. Preterm prelabor rupture of membranes (PPROM) often precedes or occurs during preterm labor. Diagnosis and management of PPROM are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6754.html" rel="external">"Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use a swab to obtain a cervicovaginal fluid specimen in case fetal fibronectin (fFN) testing is subsequently desired. The swab is rotated in the posterior fornix for 10 seconds.</p><p></p><p class="bulletIndent1">"Blind" sampling without a speculum is also acceptable. In one method, the posterior vaginal wall is depressed with an unlubricated, gloved finger and then the polyester swab is slowly passed along the finger toward the posterior fornix until resistance is felt [<a href="#rid5">5</a>]. In another method, the labia are held apart and then the swab is blindly inserted into the vagina and directed slowly toward the posterior fornix until meeting resistance [<a href="#rid6">6</a>]. In both methods, it is important to stop at the first sign of resistance to avoid rupturing exposed membranes, if present. (See <a class="local">'Fetal fibronectin for selected patients'</a> below.)</p><p></p><p class="headingAnchor" id="H1331945956"><span class="h2">Digital cervical examination</span><span class="headingEndMark"> — </span>In most patients, cervical dilation and effacement are assessed by digital examination after placenta previa and rupture of membranes have been excluded by history and physical, laboratory, and ultrasound examinations, as appropriate. A digital examination should be performed before speculum examination if the information is urgently needed to care for the patient (eg, abnormal fetal heart rate, probable advanced phase of active labor) and placenta previa is unlikely. As discussed above, cervical dilation &gt;3 cm in the presence of uterine contractions at 20+0 to 36+6 weeks supports the diagnosis of preterm labor; inhibition of acute preterm labor is less likely to be successful as the cervix dilates beyond 3 cm.</p><p>When assessing cervical dilation and effacement in the second trimester, it is important to distinguish between patients whose membranes have hour-glassed (prolapsed) through a mildly dilated and effaced cervix (which is suggestive of cervical insufficiency) and those who are in active labor with advanced cervical dilation and effacement. Transvaginal ultrasound (TVUS) assessment of the cervix can help distinguish between the two entities when the diagnosis is uncertain. (See  <a class="medical medical_review" href="/d/html/6774.html" rel="external">"Cervical insufficiency", section on 'Physical examination-based cervical insufficiency'</a> and  <a class="medical medical_review" href="/d/html/6737.html" rel="external">"Transvaginal cervical cerclage", section on 'Replace prolapsed membranes, if present'</a>.)</p><p class="headingAnchor" id="H3142287142"><span class="h2">Transvaginal ultrasound examination</span><span class="headingEndMark"> — </span>TVUS measurement of cervical length is useful for supporting or excluding the diagnosis of preterm labor when the diagnosis is unclear. A short cervix (defined here as &lt;30 mm) before 34 weeks of gestation is predictive of an increased risk for preterm birth in all populations, while a long cervix (defined here as ≥30 mm) has a high negative predictive value for preterm birth. Knowledge of cervical length in patients with threatened preterm labor may improve outcome, particularly avoidance of unnecessary hospitalization and interventions when the cervix is long, but data are limited [<a href="#rid7">7</a>].</p><p>The procedure for measurement of cervical length is described separately. (See  <a class="medical medical_review" href="/d/html/450.html" rel="external">"Short cervix before 24 weeks: Screening and management in singleton pregnancies"</a>.)</p><p class="headingAnchor" id="H3205201286"><span class="h2">Obstetric ultrasound examination</span><span class="headingEndMark"> — </span>Obstetric ultrasound examination provides useful information besides cervical length, including presence/absence of fetal, placental, and maternal anatomic abnormalities; confirmation of fetal presentation; assessment of amniotic fluid volume; and estimated fetal weight. This information may be used for counseling patients about the potential causes and outcomes of preterm birth and determining the best route of birth.</p><p class="headingAnchor" id="H1331943777"><span class="h2">Laboratory evaluation</span></p><p class="headingAnchor" id="H4259845960"><span class="h3">Overview</span><span class="headingEndMark"> — </span>We order the following laboratory tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Rectovaginal group B streptococcal (GBS) culture, if not done within the previous five weeks; antibiotic prophylaxis against GBS depends on the results. (See  <a class="medical medical_review" href="/d/html/438.html" rel="external">"Prevention of early-onset group B streptococcal disease in neonates", section on 'Special populations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine culture since asymptomatic bacteriuria and pyelonephritis are associated with an increased risk of preterm labor and birth. (See  <a class="medical medical_review" href="/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>fFN in pregnancies &lt;34 weeks of gestation with intact membranes, cervical dilation &lt;3 cm, and cervical length 20 to 30 mm on TVUS examination. (See <a class="local">'Cervical length 20 to &lt;30 mm'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for sexually transmitted infections (eg, chlamydia, gonorrhea, syphilis), depending on the patient's risk factors for these infections and, if indicated, whether antepartum testing for the infections was recently performed. (See  <a class="medical medical_review" href="/d/html/83303.html" rel="external">"Prenatal care: Second and third trimesters", section on 'Screen for sexually transmitted infections'</a>.)</p><p></p><p class="headingAnchor" id="H1331945387"><span class="h3">Fetal fibronectin for selected patients</span><span class="headingEndMark"> — </span>fFN is an extracellular matrix protein present at the decidual-chorionic interface. Disruption of this interface due to subclinical infection or inflammation, abruption, or uterine contractions releases fFN into cervicovaginal secretions, which is the basis for its use as a marker for predicting spontaneous preterm birth [<a href="#rid8">8</a>].</p><p>Measurement of fFN is performed to distinguish true preterm labor from false labor. Theoretically, accurate identification of true preterm labor provides an opportunity for interventions that can improve neonatal outcome (eg, antenatal corticosteroid therapy, antibiotic prophylaxis against group B streptococcal infection, <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> for neuroprotection, transfer to a facility with an appropriate level nursery, if necessary). The ability to rule out true preterm labor should avoid unnecessary and sometimes costly intervention for the approximately 50 percent of patients who will subsequently give birth at term despite not receiving tocolytic therapy [<a href="#rid1">1</a>].</p><p>However, fFN results alone are not useful [<a href="#rid9">9,10</a>]. In a systematic review of six randomized trials in which a total of 546 patients with threatened preterm labor were randomly assigned to management with reported or concealed fFN results, clinician knowledge of fFN results did not reduce rates of maternal hospitalization (risk ratio [RR] 1.06, 95% CI 0.79-1.43) or preterm birth &lt;34 weeks (RR 1.09, 95% CI 0.54-2.18) [<a href="#rid11">11</a>]. Use of tocolytics and <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a>, gestational age at birth, rate of respiratory distress syndrome, and number of days in a neonatal intensive care unit were similar for both groups [<a href="#rid9">9</a>]. An unexpected finding was that costs were higher in the reported group, suggesting that physicians placed greater significance on positive test results than on negative results, resulting in an overall increase in health care utilization [<a href="#rid12">12</a>]. The review excluded trials in which management involved use of both fFN and sonographic cervical length, which is our approach. We obtain fFN selectively, limiting its use to patients with cervical length 20 to 30 mm. (See <a class="local">'Cervical length 20 to &lt;30 mm'</a> below.)</p><p class="headingAnchor" id="H3323370105"><span class="h4">Qualitative fFN</span><span class="headingEndMark"> — </span>Qualitative fFN results are reported as positive or negative. A positive fFN test refers to a fFN concentration ≥50 ng/mL in cervicovaginal fluid between 22+0 and 34+6<sup> </sup>weeks of gestation in patients with intact membranes, cervical dilation &lt;3 cm, and no gross vaginal bleeding. A positive fFN result correlates with an increased risk of preterm birth within seven days.</p><p>In patients with signs and symptoms of preterm labor, a systematic review of five randomized trials and 15 diagnostic test accuracy studies evaluating cervicovaginal fFN for predicting preterm birth reported the following pooled estimates [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Birth within 7 to 10 days of testing – Sensitivity and specificity 76.7 and 82.7 percent, respectively</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Birth &lt;34 weeks of gestation – Sensitivity and specificity 69.1 and 84.4 percent, respectively</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Birth &lt;37 weeks of gestation – Sensitivity and specificity 60.8 and 82.3 percent, respectively</p><p></p><p>Positive and negative predictive values depend on the prevalence of preterm birth in the population. In a systematic review in which the prevalence of preterm birth within seven days of sampling varied from 2 to 30 percent among the included studies, the overall pretest probability of birth within seven days of testing was 7.7 percent, and based on positive or negative fFN results, the posttest probabilities were 25.9 and 2.4 percent, respectively [<a href="#rid14">14</a>].</p><p>False-positive results can occur due to ejaculate from coitus within the previous 24 hours, a grossly bloody specimen, or digital cervical examination [<a href="#rid15">15-17</a>]. Theoretically, TVUS examination may cause a false positive result, but in one study all 25 patients with a negative baseline fFN test had a second negative fFN test post-ultrasound [<a href="#rid18">18</a>]. Administration of intravaginal substances, such as lubricants, medications, or douching may interfere with the assay [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H17134444"><span class="h4">Quantitative fFN</span><span class="headingEndMark"> — </span>Quantitative measurement of fFN appears to improve predictive value compared with use of the qualitative test using a 50 ng/mL threshold [<a href="#rid20">20-22</a>]. In symptomatic patients, the positive predictive values of fFN thresholds of 10, 50, 200, and 500 ng/mL for preterm birth within 14 days were 11, 20, 37, and 46 percent, respectively, in a prospective blinded study [<a href="#rid20">20</a>]. For preterm birth &lt;34 weeks of gestation, positive predictive values for the same thresholds were 19, 32, 61, and 75 percent, respectively. Instrumentation for quantitative measurement of fFN is not commercially available in the United States.</p><p>The combination of quantitative fFN testing and cervical length measurement in symptomatic patients increases predictive value [<a href="#rid23">23</a>]. An algorithm combining quantitative fFN and cervical length, demographic information, and obstetric history (previous spontaneous preterm birth/preterm prelabor rupture of membranes or suspected preterm labor) has been incorporated into the Quantitative Instrument for the Prediction of Preterm birth App (QUiPP) for prediction of spontaneous preterm birth in Europe [<a href="#rid24">24-27</a>].</p><p class="headingAnchor" id="H2742661368"><span class="h3">Other laboratory tests</span><span class="headingEndMark"> — </span>Like fFN, placental alpha-microglobulin-1 (PAMG-1) [<a href="#rid28">28-30</a>] or insulin-like growth factor binding protein-1 (IGFBP-1) [<a href="#rid31">31</a>] in vaginal or cervical secretions suggests disruption of the fetal membranes (prelabor rupture of membranes [PROM] or labor) and are potential markers of an increased risk of preterm birth. These tests are typically used for diagnosis of PROM, whereas their utility for prediction of preterm birth has not been validated in either large or randomized clinical trials.</p><p>In the largest study, which included 796 patients with signs and symptoms of preterm labor, the sensitivities of PAMG-1 and fFN for spontaneous preterm birth within seven days were 50 percent (3/6) and 67 percent (4/6), respectively, and specificities were 98.4 percent (619/629) and 85.7 percent (539/629), respectively [<a href="#rid30">30</a>]. In a prospective study that compared PAMG-1 with pIGFBP-1 among patients in preterm labor with intact membranes, dilation ≤3 cm, and cervical length 15 to 30 mm, both tests had similar sensitivity (75 to 85 percent) for birth within seven days, but PAMG-1 was more specific (95 versus 77 percent) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H83585229"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>We make the diagnosis of preterm labor based upon clinical criteria of regular painful uterine contractions accompanied by cervical change (dilation and/or effacement). Vaginal bleeding and/or ruptured membranes in this setting increase diagnostic certainty [<a href="#rid33">33</a>]. Because the clinical findings of early labor are poorly predictive of the diagnosis, over-diagnosis is common until labor is well established.</p><p>We use the following specific criteria: Uterine contractions (≥6 in 60 minutes) <strong>plus</strong></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical dilation ≥3 cm <strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical length &lt;20 mm on transvaginal ultrasound <strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical length 20 to &lt;30 mm on transvaginal ultrasound and positive fetal fibronectin</p><p></p><p>There is an inverse relationship between cervical dilation/length and delivery interval in patients with contractions, and no threshold eliminates the possibility of preterm birth within 48 hours. When less stringent thresholds are used, the positive predictive value for true preterm labor declines and the rate of false-positive diagnosis is as high as 40 or 50 percent [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1331942126"><span class="h1">APPROACH TO TRIAGE: SINGLETON GESTATIONS</span></p><p class="headingAnchor" id="H83585762"><span class="h2">≥34 weeks of gestation</span><span class="headingEndMark"> — </span>Patients with suspected preterm labor at ≥34 weeks are admitted for observation. </p><p>After a period of four to six hours: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients found not to be in labor</strong> – Patients without progressive cervical dilation and effacement are discharged, as long as fetal well-being is confirmed (eg, reactive nonstress test) and obstetric complications associated with preterm labor, such as abruption, chorioamnionitis, and rupture of membranes, have been excluded. They are given instruction for follow-up in one to two weeks and to call sooner if experiencing additional signs or symptoms of preterm labor or other pregnancy concerns (eg, bleeding, rupture of membranes, decreased fetal activity). (See  <a class="medical medical_patient" href="/d/html/6726.html" rel="external">"Patient education: Preterm labor (Beyond the Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients found to be in labor</strong> – Patients with progressive cervical dilation and effacement are in labor and managed accordingly. (See  <a class="medical medical_review" href="/d/html/4445.html" rel="external">"Labor and delivery: Management of the normal first stage", section on 'Management of the first stage of labor'</a>.) </p><p></p><p class="bulletIndent1">The 34<sup>th</sup> week of gestation is the threshold at which perinatal morbidity and mortality are generally considered to be too low to justify the potential maternal and fetal complications and costs associated with inhibition of preterm labor, which only results in short term delay in birth (see  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Lower and upper gestational age limits'</a>). </p><p></p><p class="bulletIndent1">We typically do not administer antenatal corticosteroids after 34 weeks of gestation because of the low risk of severe respiratory morbidity at this gestational age and the potential for long-term harm following late exposure; however, this is controversial and others administer corticosteroids in this setting. The risks, benefits, and controversies regarding steroid use after 34 weeks are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '34+0 or more weeks'</a>.)</p><p></p><p class="headingAnchor" id="H83585866"><span class="h2">&lt;34 weeks of gestation</span><span class="headingEndMark"> — </span>Patients with uterine contractions and intact membranes at &lt;34 weeks of gestation are admitted for evaluation. </p><p class="headingAnchor" id="H1892621821"><span class="h3">Cervical dilation ≥3 cm</span><span class="headingEndMark"> — </span>Cervical dilation ≥3 cm supports the diagnosis of preterm labor. Further diagnostic evaluation with sonographic measurement of cervical length or laboratory assessment of fetal fibronectin (fFN) is not performed because these tests do not enhance diagnostic accuracy in this setting. Management is directed at reducing the morbidity and mortality of preterm birth. (See <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> below.)</p><p class="headingAnchor" id="H119264816"><span class="h3">Cervical dilation &lt;3 cm</span><span class="headingEndMark"> — </span>The diagnosis is less clear when cervical dilation is &lt;3 cm. Our approach to diagnosis and treatment in these cases is shown in the algorithm and discussed in the sections below  (<a class="graphic graphic_algorithm graphicRef78336" href="/d/graphic/78336.html" rel="external">algorithm 1</a>). The use of cervical length measurement, with fFN in selected cases, is based upon clinical experience and accumulating data on risk of preterm birth according to cervical length on transvaginal ultrasound, in the absence of abruption [<a href="#rid2">2,33-38</a>].</p><p class="headingAnchor" id="H1331942419"><span class="h4">Cervical length 20 to &lt;30 mm</span><span class="headingEndMark"> — </span>Symptomatic patients with cervical dilation &lt;3 cm and cervical length 20 to &lt;30 mm are at increased risk of preterm birth compared with those with longer cervical lengths, but most of these patients do not give birth preterm. Therefore, for this subgroup of patients, we send a cervicovaginal sample for fFN testing (see <a class="local">'Fetal fibronectin for selected patients'</a> above). We believe that selective testing helps reduce diagnostic uncertainty and, in turn, unnecessary intervention, by identifying the significant proportion of patients in this group who are at low (&lt;5 percent) risk of giving birth within seven days [<a href="#rid39">39</a>]. Since the test is expensive, reducing the number of patients tested by one-third is advantageous [<a href="#rid40">40-42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>If the fFN test is positive, we begin interventions to reduce morbidity associated with preterm birth (see <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fFN test is negative, we discharge the patient after 6 to 12 hours of observation, given its high negative predictive value (98 to 100 percent for birth within 7 or 14 days [<a href="#rid43">43</a>]) [<a href="#rid13">13</a>].</p><p></p><p>Use of sonographic cervical length and fFN determinations to differentiate true labor from false labor in preterm symptomatic patients is supported by the Society for Maternal-Fetal Medicine [<a href="#rid44">44</a>], although high quality evidence of efficacy is not available.</p><p class="headingAnchor" id="H1331942451"><span class="h4">Cervical length &lt;20 mm</span><span class="headingEndMark"> — </span>Symptomatic patients with cervical length &lt;20 mm are at high risk (&gt;25 percent) of giving birth within seven days; the addition of fFN testing does not significantly improve the predictive value of cervical length measurement alone [<a href="#rid39">39-41,45,46</a>]. Therefore, we do not send their cervicovaginal samples to the laboratory for fFN testing and we begin interventions to reduce morbidity associated with preterm birth. (See <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> below.)</p><p class="headingAnchor" id="H1331944201"><span class="h4">Cervical length ≥30 mm</span><span class="headingEndMark"> — </span>Approximately 50 percent of patients with symptoms of preterm labor have a transvaginal ultrasound cervical length ≥30 mm [<a href="#rid35">35</a>]. These patients are at low risk (&lt;5 percent) of giving birth within seven days, regardless of fFN result; the addition of fFN testing does not significantly improve the predictive value of cervical length measurement alone [<a href="#rid39">39,40,45,46</a>]. Therefore, we do not send their cervicovaginal samples to the laboratory for fFN testing.</p><p>After an observation period of four to six hours, patients without progressive cervical dilation and effacement are discharged, as long as fetal well-being is confirmed (eg, reactive nonstress test) and obstetric complications associated with preterm labor, such as abruption, chorioamnionitis, and rupture of membranes, have been excluded. We arrange follow-up in one to two weeks and give the patient instructions to call if they experience additional signs or symptoms of preterm labor or have other pregnancy concerns (eg, bleeding, rupture of membranes, decreased fetal activity). (See  <a class="medical medical_patient" href="/d/html/6726.html" rel="external">"Patient education: Preterm labor (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H2479718427"><span class="h1">APPROACH TO TRIAGE: TWIN GESTATIONS</span><span class="headingEndMark"> — </span>The prediction of preterm birth based on cervical length measurement is somewhat different for twin pregnancies, which necessitates some changes in triage criteria. The optimal cervical length threshold appears to be higher due to the higher baseline risk for preterm birth in twins compared with singletons; however, less data are available for establishing appropriate thresholds [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H1587882699"><span class="h2">≥34 weeks of gestation</span><span class="headingEndMark"> — </span>Triage is the same as for singletons. (See <a class="local">'≥34 weeks of gestation'</a> above.)</p><p class="headingAnchor" id="H1370643971"><span class="h2">&lt;34 weeks of gestation</span><span class="headingEndMark"> — </span>For twin pregnancies &lt;34 weeks with uterine contractions and intact membranes: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cervical dilation ≥3 cm</strong> – Cervical dilation ≥3 cm supports the diagnosis of preterm labor; further diagnostic evaluation with sonographic measurement of cervical length or laboratory assessment of fetal fibronectin (fFN) does not enhance diagnostic accuracy. Treatment of preterm labor is initiated. (See <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cervical dilation &lt;3 cm</strong> – The diagnosis of preterm labor is less clear with cervical dilation &lt;3 cm, so a transvaginal ultrasound measurement of cervical length is obtained.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cervical length &gt;35 mm</strong> – Patients with cervical length &gt;35 mm and no cervical change on digital examination after a four- to six-hour period of observation are at low risk for preterm birth, and can be discharged home, as long as fetal well-being is confirmed, maternal status is stable, and there are no additional maternal concerns.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cervical length &lt;25 mm</strong> – Patients with cervical length &lt;25 mm are at high risk of preterm birth; therefore, we begin interventions to reduce morbidity associated with preterm birth. (See <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cervical length 25 to 35 mm</strong> – Patients with cervical length 25 to 35 mm on transvaginal ultrasound examination undergo fFN testing. If the test is positive, we begin interventions to reduce morbidity associated with preterm birth (see <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> below). If the test is negative, we discharge the patient after a 6- to 12-hour period of observation.</p><p></p><p class="headingAnchor" id="H1331942469"><span class="h1">INITIAL TREATMENT OF PRETERM LABOR &lt;34 WEEKS</span><span class="headingEndMark"> — </span>We hospitalize patients diagnosed with preterm labor &lt;34 weeks of gestation and initiate the following treatments, in general agreement with recommendations from the American College of Obstetricians and Gynecologists [<a href="#rid49">49</a>]:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antenatal corticosteroids</strong> – A course of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> to reduce neonatal morbidity and mortality associated with preterm birth. A single rescue course of antenatal steroids is indicated for pregnancies &lt;34+0 weeks of gestation that are at high risk of preterm delivery within the next seven days and in which the prior course of ACS was administered more than 14 days previously [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tocolytics</strong> – Tocolytic drugs for up to 48 hours to delay birth so that <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> given to the mother can achieve its maximum fetal effect. Inhibition of acute preterm labor and management of pregnancies after successful inhibition are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor"</a> and  <a class="medical medical_review" href="/d/html/6795.html" rel="external">"Management of pregnancy after resolution of an episode of acute idiopathic preterm labor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GBS prophylaxis</strong> – Antibiotics for prophylaxis against early-onset neonatal group B streptococcal (GBS) infection. (See  <a class="medical medical_review" href="/d/html/438.html" rel="external">"Prevention of early-onset group B streptococcal disease in neonates", section on 'Special populations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroprotection</strong> – <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> for pregnancies &lt;32 weeks of gestation. In utero exposure to magnesium sulfate provides neuroprotection against cerebral palsy and other types of severe motor dysfunction in offspring born preterm. (See  <a class="medical medical_review" href="/d/html/4481.html" rel="external">"Neuroprotective effects of in utero exposure to magnesium sulfate"</a>.)</p><p></p><p>Antibiotic therapy has no role in the treatment of acute preterm labor in the absence of a documented infection or GBS prophylaxis [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Antibiotic therapy'</a>.)</p><p><a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">Progesterone</a> supplementation has no role in the treatment of acute preterm labor. (See  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Progesterone supplementation'</a>.)</p><p class="headingAnchor" id="H2405712393"><span class="h1">OUTCOME</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall frequency of preterm birth among patients with suspected preterm labor</strong> – Tocolytic therapy is more effective than placebo for delaying birth for 48 hours in randomized trials; however, even when tocolytics are not administered, approximately 50 percent of patients diagnosed with preterm labor give birth at term [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Efficacy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term maternal outcome after giving birth preterm</strong> – Mothers who give birth preterm are at risk for recurrent preterm birth. (See  <a class="medical medical_review" href="/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Past history of preterm birth'</a>.)</p><p></p><p class="bulletIndent1">They also appear to be at increased risk for cardiovascular morbidity and mortality years after the birth. (See  <a class="medical medical_review" href="/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Long-term maternal consequences'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric outcome after preterm birth </strong>– Newborn outcomes of preterm birth are reviewed in the following topics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4965.html" rel="external">"Overview of short-term complications in preterm infants"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5034.html" rel="external">"Late preterm infants"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5033.html" rel="external">"Overview of the long-term complications of preterm birth"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4967.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric outcome after suspected preterm labor</strong> – Whether a history of suspected preterm labor is associated with adverse neonatal outcome in patients who go on to have term births is controversial. These patients may have underlying pathology, such as subclinical intra-amniotic inflammation, that may adversely affect fetal growth or development even though they go on to have a term birth [<a href="#rid53">53-57</a>].</p><p></p><p class="headingAnchor" id="H1383291859"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114351.html" rel="external">"Society guideline links: Preterm labor and birth"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15609.html" rel="external">"Patient education: Preterm labor (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16909.html" rel="external">"Patient education: How to tell when labor starts (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/6726.html" rel="external">"Patient education: Preterm labor (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs and symptoms of preterm labor</strong> – Early signs and symptoms of both preterm and term labor are nonspecific and include: menstrual-like cramping; mild, irregular contractions; low back ache; pressure sensation in the vagina; vaginal discharge of mucus, which may be clear, pink, or slightly bloody (ie, mucus plug, bloody show). (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of preterm labor in singleton pregnancies</strong> – The diagnosis of preterm labor is based on presence of regular painful uterine contractions accompanied by cervical dilation and/or effacement. We use the following specific criteria for diagnosis: Uterine contractions (≥6 in 60 minutes) and (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical dilation ≥3 cm <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical length &lt;20 mm on transvaginal ultrasound <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical length 20 to &lt;30 mm on transvaginal ultrasound and positive fetal fibronectin (fFN)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of suspected preterm labor in singleton pregnancies</strong> – The 34<sup>th</sup> week of gestation is the threshold at which perinatal morbidity and mortality are too low to justify the potential maternal and fetal complications and costs associated with inhibition of preterm labor, which only results in short-term delay in birth. (See <a class="local">'≥34 weeks of gestation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For pregnancies ≥34 weeks of gestation</strong>, patients without progressive cervical dilation and effacement after an observation period of four to six hours can be discharged to home, as long as fetal well-being is confirmed and obstetric complications associated with preterm labor, such as abruption, chorioamnionitis, and membrane rupture, have been excluded. Patients in preterm labor are admitted to give birth. (See <a class="local">'≥34 weeks of gestation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For pregnancies &lt;34 weeks and cervical dilation ≥3 cm</strong>, we administer tocolytic drugs for up to 48 hours, antibiotics for group B streptococcal chemoprophylaxis (when appropriate), and antenatal <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a>. <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> is administered for neuroprotection to pregnancies &lt;32 weeks of gestation. (See <a class="local">'Initial treatment of preterm labor &lt;34 weeks'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For pregnancies &lt;34 weeks of gestation and cervical dilation &lt;3 cm</strong>, transvaginal ultrasound measurement of cervical length and laboratory analysis of cervicovaginal fFN level help to support or exclude the diagnosis of preterm labor, as described in the algorithm  (<a class="graphic graphic_algorithm graphicRef78336" href="/d/graphic/78336.html" rel="external">algorithm 1</a>). For patients diagnosed with preterm labor, we administer tocolytic drugs for up to 48 hours, antibiotics for group B streptococcal chemoprophylaxis (when appropriate), and antenatal <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a>. <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> is administered for neuroprotection to pregnancies &lt;32 weeks of gestation. (See <a class="local">'&lt;34 weeks of gestation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and management in twin pregnancies </strong>–The diagnosis of preterm labor in twin pregnancies is based on the same uterine contraction criteria as for singleton pregnancies, and management of preterm labor in twin gestations ≥34 weeks of gestation or &lt;34 weeks with cervical dilation ≥3 cm is also similar to that for singletons, but cervical length criteria for triage of twin pregnancies &lt;34 weeks with cervical dilation &lt;3 cm is different. (See <a class="local">'Approach to triage: Twin gestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For twin pregnancies &lt;34 weeks and cervical dilation &lt;3 cm, transvaginal ultrasound measurement of cervical length and laboratory analysis of cervicovaginal fFN level help to support or exclude the diagnosis of preterm labor:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cervical length &gt;35 mm and no cervical change on digital examination after a four- to six-hour period of observation – Low risk for preterm birth: discharge.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cervical length &lt;25 mm – High risk of preterm birth: initiate interventions to reduce morbidity associated with preterm birth.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cervical length 25 to 35 mm – fFN testing. If positive, initiate interventions to reduce morbidity associated with preterm birth. If negative, discharge after a 6- to 12-hour period of observation.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Haas DM, Imperiale TF, Kirkpatrick PR, et al. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113:585.</a></li><li><a class="nounderline abstract_t">Sotiriadis A, Papatheodorou S, Kavvadias A, Makrydimas G. Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. Ultrasound Obstet Gynecol 2010; 35:54.</a></li><li><a class="nounderline abstract_t">Iams JD, Cebrik D, Lynch C, et al. The rate of cervical change and the phenotype of spontaneous preterm birth. Am J Obstet Gynecol 2011; 205:130.e1.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins—Obstetrics and the American Institute of Ultrasound in Medicine. Practice Bulletin No. 175: Ultrasound in Pregnancy. Obstet Gynecol 2016; 128:e241. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Stafford IP, Garite TJ, Dildy GA, et al. A comparison of speculum and nonspeculum collection of cervicovaginal specimens for fetal fibronectin testing. Am J Obstet Gynecol 2008; 199:131.e1.</a></li><li><a class="nounderline abstract_t">Roman AS, Koklanaris N, Paidas MJ, et al. "Blind" vaginal fetal fibronectin as a predictor of spontaneous preterm delivery. Obstet Gynecol 2005; 105:285.</a></li><li><a class="nounderline abstract_t">Berghella V, Palacio M, Ness A, et al. Cervical length screening for prevention of preterm birth in singleton pregnancy with threatened preterm labor: systematic review and meta-analysis of randomized controlled trials using individual patient-level data. Ultrasound Obstet Gynecol 2017; 49:322.</a></li><li><a class="nounderline abstract_t">Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol 1991; 138:537.</a></li><li><a class="nounderline abstract_t">Berghella V, Saccone G. Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2016; 215:431.</a></li><li><a class="nounderline abstract_t">Chuck AW, Thanh NX, Chari RS, et al. Post-Policy Implementation Review of Rapid Fetal Fibronectin (fFN) Testing for Preterm Labour in Alberta. J Obstet Gynaecol Can 2016; 38:659.</a></li><li><a class="nounderline abstract_t">Berghella V, Saccone G. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst Rev 2019; 7:CD006843.</a></li><li><a class="nounderline abstract_t">Chiossi G, Saade GR, Sibai B, Berghella V. Using Cervical Length Measurement for Lower Spontaneous Preterm Birth Rates Among Women With Threatened Preterm Labor. Obstet Gynecol 2018; 132:102.</a></li><li><a class="nounderline abstract_t">Deshpande SN, van Asselt AD, Tomini F, et al. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. Health Technol Assess 2013; 17:1.</a></li><li><a class="nounderline abstract_t">Sanchez-Ramos L, Delke I, Zamora J, Kaunitz AM. Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis. Obstet Gynecol 2009; 114:631.</a></li><li><a class="nounderline abstract_t">McKenna DS, Chung K, Iams JD. Effect of digital cervical examination on the expression of fetal fibronectin. J Reprod Med 1999; 44:796.</a></li><li><a class="nounderline abstract_t">McLaren JS, Hezelgrave NL, Ayubi H, et al. Prediction of spontaneous preterm birth using quantitative fetal fibronectin after recent sexual intercourse. Am J Obstet Gynecol 2015; 212:89.e1.</a></li><li><a class="nounderline abstract_t">Shimoya K, Hashimoto K, Shimizu T, et al. Cervical fluid oncofetal fibronectin as a predictor of early ectopic pregnancy. Is it affected by blood contamination? J Reprod Med 2002; 47:640.</a></li><li><a class="nounderline abstract_t">Ben-Haroush A, Poran E, Yogev Y, Glezerman M. Vaginal fetal fibronectin evaluation before and immediately after ultrasonographic vaginal cervical length measurements in symptomatic women at risk of preterm birth: a pilot study. J Matern Fetal Neonatal Med 2010; 23:854.</a></li><li class="breakAll">http://www.ffntest.com/pdfs/rapid_ffn_product_insert_lettersize.pdf (Accessed on May 04, 2015).</li><li><a class="nounderline abstract_t">Abbott DS, Radford SK, Seed PT, et al. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J Obstet Gynecol 2013; 208:122.e1.</a></li><li><a class="nounderline abstract_t">Kuhrt K, Unwin C, Hezelgrave N, et al. Endocervical and high vaginal quantitative fetal fibronectin in predicting preterm birth. J Matern Fetal Neonatal Med 2014; 27:1576.</a></li><li><a class="nounderline abstract_t">Kuhrt K, Hezelgrave N, Foster C, et al. Development and validation of a tool incorporating quantitative fetal fibronectin to predict spontaneous preterm birth in symptomatic women. Ultrasound Obstet Gynecol 2016; 47:210.</a></li><li><a class="nounderline abstract_t">Bruijn MM, Kamphuis EI, Hoesli IM, et al. The predictive value of quantitative fibronectin testing in combination with cervical length measurement in symptomatic women. Am J Obstet Gynecol 2016; 215:793.e1.</a></li><li><a class="nounderline abstract_t">Kuhrt K, Smout E, Hezelgrave N, et al. Development and validation of a tool incorporating cervical length and quantitative fetal fibronectin to predict spontaneous preterm birth in asymptomatic high-risk women. Ultrasound Obstet Gynecol 2016; 47:104.</a></li><li class="breakAll">www.QUiPP.org.</li><li><a class="nounderline abstract_t">Watson HA, Carter J, Seed PT, et al. The QUiPP App: a safe alternative to a treat-all strategy for threatened preterm labor. Ultrasound Obstet Gynecol 2017; 50:342.</a></li><li><a class="nounderline abstract_t">Dehaene I, Steen J, Vandewiele G, et al. The web-based application "QUiPP v.2" for the prediction of preterm birth in symptomatic women is not yet ready for worldwide clinical use: ten reflections on development, validation and use. Arch Gynecol Obstet 2022; 306:571.</a></li><li><a class="nounderline abstract_t">Ehsanipoor RM, Swank ML, Jwa SC, et al. Placental α-Microglobulin-1 in Vaginal Secretions of Women with Evidence of Preterm Labor. Am J Perinatol 2016; 33:208.</a></li><li><a class="nounderline abstract_t">Nikolova T, Bayev O, Nikolova N, Di Renzo GC. Comparison of a novel test for placental alpha microglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor. J Perinat Med 2015; 43:395.</a></li><li><a class="nounderline abstract_t">Wing DA, Haeri S, Silber AC, et al. Placental Alpha Microglobulin-1 Compared With Fetal Fibronectin to Predict Preterm Delivery in Symptomatic Women. Obstet Gynecol 2017; 130:1183.</a></li><li><a class="nounderline abstract_t">Ting HS, Chin PS, Yeo GS, Kwek K. Comparison of bedside test kits for prediction of preterm delivery: phosphorylated insulin-like growth factor binding protein-1 (pIGFBP-1) test and fetal fibronectin test. Ann Acad Med Singapore 2007; 36:399.</a></li><li><a class="nounderline abstract_t">Nikolova T, Uotila J, Nikolova N, et al. Prediction of spontaneous preterm delivery in women presenting with premature labor: a comparison of placenta alpha microglobulin-1, phosphorylated insulin-like growth factor binding protein-1, and cervical length. Am J Obstet Gynecol 2018; 219:610.e1.</a></li><li><a class="nounderline abstract_t">Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003; 101:402.</a></li><li><a class="nounderline abstract_t">Tsoi E, Fuchs IB, Rane S, et al. Sonographic measurement of cervical length in threatened preterm labor in singleton pregnancies with intact membranes. Ultrasound Obstet Gynecol 2005; 25:353.</a></li><li><a class="nounderline abstract_t">Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007; 197:426.e1.</a></li><li><a class="nounderline abstract_t">Murakawa H, Utumi T, Hasegawa I, et al. Evaluation of threatened preterm delivery by transvaginal ultrasonographic measurement of cervical length. Obstet Gynecol 1993; 82:829.</a></li><li><a class="nounderline abstract_t">Tsoi E, Akmal S, Rane S, et al. Ultrasound assessment of cervical length in threatened preterm labor. Ultrasound Obstet Gynecol 2003; 21:552.</a></li><li><a class="nounderline abstract_t">Melamed N, Hiersch L, Domniz N, et al. Predictive value of cervical length in women with threatened preterm labor. Obstet Gynecol 2013; 122:1279.</a></li><li><a class="nounderline abstract_t">van Baaren GJ, Vis JY, Wilms FF, et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123:1185.</a></li><li><a class="nounderline abstract_t">Schmitz T, Maillard F, Bessard-Bacquaert S, et al. Selective use of fetal fibronectin detection after cervical length measurement to predict spontaneous preterm delivery in women with preterm labor. Am J Obstet Gynecol 2006; 194:138.</a></li><li><a class="nounderline abstract_t">Audibert F, Fortin S, Delvin E, et al. Contingent use of fetal fibronectin testing and cervical length measurement in women with preterm labour. J Obstet Gynaecol Can 2010; 32:307.</a></li><li><a class="nounderline abstract_t">van Baaren GJ, Vis JY, Wilms FF, et al. Cost-effectiveness of diagnostic testing strategies including cervical-length measurement and fibronectin testing in women with symptoms of preterm labor. Ultrasound Obstet Gynecol 2018; 51:596.</a></li><li><a class="nounderline abstract_t">Foster C, Shennan AH. Fetal fibronectin as a biomarker of preterm labor: a review of the literature and advances in its clinical use. Biomark Med 2014; 8:471.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM). Electronic address: <span class="__cf_email__" data-cfemail="dcaca9beaf9cafb1bab1f2b3aebb">[email protected]</span>, McIntosh J, Feltovich H, et al. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. Am J Obstet Gynecol 2016; 215:B2.</a></li><li><a class="nounderline abstract_t">Gomez R, Romero R, Medina L, et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005; 192:350.</a></li><li><a class="nounderline abstract_t">Hincz P, Wilczynski J, Kozarzewski M, Szaflik K. Two-step test: the combined use of fetal fibronectin and sonographic examination of the uterine cervix for prediction of preterm delivery in symptomatic patients. Acta Obstet Gynecol Scand 2002; 81:58.</a></li><li><a class="nounderline abstract_t">Fox NS, Saltzman DH, Fishman A, et al. Gestational age at cervical length and fetal fibronectin assessment and the incidence of spontaneous preterm birth in twins. J Ultrasound Med 2015; 34:977.</a></li><li><a class="nounderline abstract_t">Melamed N, Hiersch L, Gabbay-Benziv R, et al. Predictive value of cervical length in women with twin pregnancy presenting with threatened preterm labor. Ultrasound Obstet Gynecol 2015; 46:73.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol 2016; 128:e155. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Committee on Obstetric Practice. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol 2017; 130:e102.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstet Gynecol 2018; 132:e103.</a></li><li><a class="nounderline abstract_t">Hackney DN, Olson-Chen C, Thornburg LL. What do we know about the natural outcomes of preterm labour? A systematic review and meta-analysis of women without tocolysis in preterm labour. Paediatr Perinat Epidemiol 2013; 27:452.</a></li><li><a class="nounderline abstract_t">Paules C, Pueyo V, Martí E, et al. Threatened preterm labor is a risk factor for impaired cognitive development in early childhood. Am J Obstet Gynecol 2017; 216:157.e1.</a></li><li><a class="nounderline abstract_t">Romero R, Erez O, Maymon E, Pacora P. Is an episode of suspected preterm labor that subsequently leads to a term delivery benign? Am J Obstet Gynecol 2017; 216:89.</a></li><li><a class="nounderline abstract_t">Campbell MK, Cartier S, Xie B, et al. Determinants of small for gestational age birth at term. Paediatr Perinat Epidemiol 2012; 26:525.</a></li><li><a class="nounderline abstract_t">Espinoza J, Kusanovic JP, Kim CJ, et al. An episode of preterm labor is a risk factor for the birth of a small-for-gestational-age neonate. Am J Obstet Gynecol 2007; 196:574.e1.</a></li><li><a class="nounderline abstract_t">Zoabi L, Weintraub AY, Novak L, et al. Do patients who deliver at term after being hospitalized for preterm contractions have an increased risk for obstetrical complications? Arch Gynecol Obstet 2013; 288:537.</a></li></ol></div><div id="topicVersionRevision">Topic 6798 Version 90.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300321" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tocolytic therapy: a meta-analysis and decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20014326" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22088837" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The rate of cervical change and the phenotype of spontaneous preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875472" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Practice Bulletin No. 175: Ultrasound in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355785" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A comparison of speculum and nonspeculum collection of cervicovaginal specimens for fetal fibronectin testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684153" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : "Blind" vaginal fetal fibronectin as a predictor of spontaneous preterm delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27997053" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cervical length screening for prevention of preterm birth in singleton pregnancy with threatened preterm labor: systematic review and meta-analysis of randomized controlled trials using individual patient-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2000933" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Is oncofetal fibronectin a trophoblast glue for human implantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133012" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and metaanalysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27591351" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Post-Policy Implementation Review of Rapid Fetal Fibronectin (fFN) Testing for Preterm Labour in Alberta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356681" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fetal fibronectin testing for reducing the risk of preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889763" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Using Cervical Length Measurement for Lower Spontaneous Preterm Birth Rates Among Women With Threatened Preterm Labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24060096" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19701045" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10509304" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of digital cervical examination on the expression of fetal fibronectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24992691" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prediction of spontaneous preterm birth using quantitative fetal fibronectin after recent sexual intercourse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12216430" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cervical fluid oncofetal fibronectin as a predictor of early ectopic pregnancy. Is it affected by blood contamination?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903114" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vaginal fetal fibronectin evaluation before and immediately after ultrasonographic vaginal cervical length measurements in symptomatic women at risk of preterm birth: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903114" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vaginal fetal fibronectin evaluation before and immediately after ultrasonographic vaginal cervical length measurements in symptomatic women at risk of preterm birth: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23164760" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24294948" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Endocervical and high vaginal quantitative fetal fibronectin in predicting preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964191" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development and validation of a tool incorporating quantitative fetal fibronectin to predict spontaneous preterm birth in symptomatic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542720" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The predictive value of quantitative fibronectin testing in combination with cervical length measurement in symptomatic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25846437" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Development and validation of a tool incorporating cervical length and quantitative fetal fibronectin to predict spontaneous preterm birth in asymptomatic high-risk women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25846437" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Development and validation of a tool incorporating cervical length and quantitative fetal fibronectin to predict spontaneous preterm birth in asymptomatic high-risk women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436125" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The QUiPP App: a safe alternative to a treat-all strategy for threatened preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35106643" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The web-based application "QUiPP v.2" for the prediction of preterm birth in symptomatic women is not yet ready for worldwide clinical use: ten reflections on development, validation and use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26368914" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Placentalα-Microglobulin-1 in Vaginal Secretions of Women with Evidence of Preterm Labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25562603" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of a novel test for placental alpha microglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112664" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Placental Alpha Microglobulin-1 Compared With Fetal Fibronectin to Predict Preterm Delivery in Symptomatic Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597963" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of bedside test kits for prediction of preterm delivery: phosphorylated insulin-like growth factor binding protein-1 (pIGFBP-1) test and fetal fibronectin test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30240653" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prediction of spontaneous preterm delivery in women presenting with premature labor: a comparison of placenta alpha microglobulin-1, phosphorylated insulin-like growth factor binding protein-1, and cervical length.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576267" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prediction and early detection of preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15736212" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sonographic measurement of cervical length in threatened preterm labor in singleton pregnancies with intact membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904989" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414332" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluation of threatened preterm delivery by transvaginal ultrasonographic measurement of cervical length.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808671" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ultrasound assessment of cervical length in threatened preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201691" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictive value of cervical length in women with threatened preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24807328" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389023" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Selective use of fetal fibronectin detection after cervical length measurement to predict spontaneous preterm delivery in women with preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500936" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Contingent use of fetal fibronectin testing and cervical length measurement in women with preterm labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28370518" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cost-effectiveness of diagnostic testing strategies including cervical-length measurement and fibronectin testing in women with symptoms of preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24796611" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fetal fibronectin as a biomarker of preterm labor: a review of the literature and advances in its clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133011" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695971" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11942889" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Two-step test: the combined use of fetal fibronectin and sonographic examination of the uterine cervix for prediction of preterm delivery in symptomatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26014316" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gestational age at cervical length and fetal fibronectin assessment and the incidence of spontaneous preterm birth in twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251479" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Predictive value of cervical length in women with twin pregnancy presenting with threatened preterm labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27661654" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Practice Bulletin No. 171: Management of Preterm Labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742678" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30134425" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23930781" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : What do we know about the natural outcomes of preterm labour? A systematic review and meta-analysis of women without tocolysis in preterm labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780701" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Threatened preterm labor is a risk factor for impaired cognitive development in early childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28148450" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Is an episode of suspected preterm labor that subsequently leads to a term delivery benign?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23061688" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Determinants of small for gestational age birth at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547901" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : An episode of preterm labor is a risk factor for the birth of a small-for-gestational-age neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23529685" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Do patients who deliver at term after being hospitalized for preterm contractions have an increased risk for obstetrical complications?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
